Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
For Research Purposes Only
Out of StockCortagen
Third-Party TestedPurity Standards
Total
$49.99Size
Quantity
1
Bundle & Save
Molecular Profile
Molecular Profile
Type
Synthetic linear tetrapeptide
Molecular formula
C18H30N4O9
Molecular weight
446.45 g/mol
Amino acids
4
Sequence
Ala-Glu-Asp-Leu
Modification
Unmodified free N-/C-termini; documented in the originating patent as an acetate salt
Mechanism & Target Class
Mechanism & Target Class
Cortagen belongs to the Khavinson class of short regulatory peptides — sequences of 2–7 amino acid residues proposed to act as epigenetic modulators by penetrating cell nuclei and interacting directly with DNA and histone proteins rather than through classical receptor engagement. In vitro biophysical characterization (Morozova et al., 2017) using UV spectrophotometry, circular dichroism, and viscometry reports that AEDL forms a complex with double-stranded DNA at the guanine N7 position in the major groove without visible distortion of the double-helix structure. Differential scanning microcalorimetry work (Monaselidze et al., 2011) documents a DNA-thermostabilizing interaction with calf thymus and mouse liver DNA across a defined molar-ratio range, characterized as non-sequence-specific. Docking-based spatial modeling (Khavinson, Lin'kova & Tarnovskaya, 2016) assigns the AEDL and EDL sequences to a CTCC tetranucleotide binding motif at gene-promoter sites. Histone-binding experiments (Fedoreyeva, Vanyushin & Baranova, 2020) report AEDL interaction with linker histone H1 and core histone H3 associated with remodeling of condensed-chromatin domains. At the transcript level, AEDL is studied in human bronchial epithelial cell cultures for association with expression of differentiation factors NKX2-1, SCGB1A1, SCGB3A2, FOXA1, and FOXA2, mucin and surfactant genes MUC4, MUC5AC, and SFTPA1, and cell-cycle and signaling proteins Ki67, Mcl-1, p53, CD79, and NOS-3.
Storage & Handling
Storage & Handling
Lyophilized
−20 °C, protected from light and moisture
documented in the originating patent as a white amorphous odorless powder.
As an unprotected tetrapeptide composed of common L-amino acids, AEDL would be expected to be susceptible to proteolytic degradation; no formal pharmacokinetic study measuring the intact peptide was identified in the verified literature.
References
References
Reviews
- 1
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR (2021). Molecules
- 2
Khavinson VK, Lin'kova NS, Tarnovskaya SI, et al. (2016). Bulletin of Experimental Biology and Medicine
Reviews
- 3
Vanyushin BF, Khavinson VK (2016). Epigenetics – A Different Way of Looking at Genetics (Springer)
Primary research
- 4
Lazareva EM, Kazakov EP, Dilovarova TA, Kononenko NV, Fedoreyeva LI (2025). International Journal of Molecular Sciences
- 5
Fedoreyeva LI, Vanyushin BF, Baranova EN (2020). AIMS Biophysics
- 6
Morozova EA, Lin'kova NS, Khavinson VK, Soloviev AY, Kasyanenko NA (2017). Journal of Structural Chemistry
- 7
Fedoreyeva LI, Dilovarova TA, Ashapkin VV, et al. (2017). Biochemistry (Moscow)
- 8
Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, et al. (2015). Bulletin of Experimental Biology and Medicine
- 9
Khavinson VK, Tendler SM, Vanyushin BF, et al. (2014). Lung
- 10
Khavinson VK, Linkova NS, Polyakova VO, et al. (2012). Bulletin of Experimental Biology and Medicine
- 11
Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF (2011). Biochemistry (Moscow)
- 12
Monaselidze JR, Khavinson VK, Gorgoshidze MZ, et al. (2011). Bulletin of Experimental Biology and Medicine
- 13
Khavinson VK, Ryzhak GA, et al. (2009). US Patent 7,625,870
- 14
Khavinson VK (2001). Bulletin of Experimental Biology and Medicine
- 15
Turchaninova LN, Kolosova LI, Malinin VV, Moiseeva AB, Nozdrachev AD, Khavinson VK (2000). Bulletin of Experimental Biology and Medicine
- 16
Anisimov SV, Boheler KR, Khavinson VK, Anisimov VN (2004). Neuro Endocrinology Letters
- 17
Zarubina IV, Shabanov PD (2011). Eksperimental'naia i Klinicheskaia Farmakologiia
- 18
Shabanov PD, Vislobokov AI (2013). Reviews on Clinical Pharmacology and Drug Therapy
- 19
Lezhava T, Monaselidze J, Jokhadze T, Buadze M, Gaiozishvili M (2015). International Journal of Peptide Research and Therapeutics
- 20
Lezhava T, Jokhadze T, Monaselidze J, Buadze T, Gaiozishvili M, Sigua T (2020). Georgian Medical News
- 21
Khavinson VK, Lin'kova NS, Tarnovskaya SI, Umnov RS, Elashkina EV, Durnova AO (2014). Bulletin of Experimental Biology and Medicine
- 22
Caputi S, Trubiani O, Sinjari B, Trofimova S, Diomede F, Linkova N, Diatlova A, Khavinson V (2019). International Journal of Immunopathology and Pharmacology
Primary Database
Primary Database
Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.
